CFO Catinazzo sells 187,163 shares ($3.2M) via scheduled 10b5-1 plan; retains 177,461 shares plus 223,440 stock options.
Thomas Catinazzo, CFO of Relay Therapeutics, executed 4 separate sales totaling 187,163 shares for $3,176,864.79 on 2026-06-22 at a blended average price of $16.97, reducing his direct holdings by 51.3% to 177,461 shares. The transaction was conducted under a pre-arranged 10b5-1 trading plan adopted 2025-10-30, making it scheduled rather than discretionary. After the sale, Catinazzo retains 223,440 shares through stock option holdings, meaning his economic interest in the company remains substantial. The sale occurs against a backdrop of strong recent stock performance (30-day change +33.3%, 90-day change +78.2%) and an unprofitable company (most recent quarter revenue $3.0M, full-year net income $-73.3M), though the stock is currently at $18.03, above the transaction prices.